15 results
8-K
EX-10.2
RNXT
RenovoRx Inc
3 Apr 23
RenovoRx, Inc. Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:45pm
of, the uses of, the distribution of, the manufacturing or packaging of, the testing of, the sale of, or the labeling and promotion of any
10-K
2021 FY
RNXT
RenovoRx Inc
30 Mar 22
Annual report
7:21am
-packaging with the RenovoCath. The formulation of gemcitabine used in the TIGeR-PaC Phase 3 trial and in the commercial setting will be identical, however
424B4
RNXT
RenovoRx Inc
27 Aug 21
Prospectus supplement with pricing info
6:06am
manufacturing organizations for gemcitabine production, relabeling and co-packaging with the RenovoCath. The formulation of gemcitabine used in the TIGeR
S-1/A
EX-1.1
okfpu4847xf7cq603
5 Aug 21
IPO registration (amended)
5:29pm
S-1/A
03oks9vma9l88kdmba4
5 Aug 21
IPO registration (amended)
5:29pm
S-1
z3kiwst9jytlhsg
21 Jul 21
IPO registration
5:15pm
DRS/A
tiot0j8xnu k7l
15 Jun 21
Draft registration statement (amended)
12:00am
DRS/A
bsci5tvp47cxfiufbuza
12 May 21
Draft registration statement (amended)
12:00am
DRS
fmzkdd lgl7
2 Apr 21
Draft registration statement
12:00am
- Prev
- 1
- Next